Phase 2 Study of JNJ-79635322 Injection for Adults With Relapsed or Refractory Multiple Myeloma Who Have Had at Least 3 Prior Treatments Including a PI, IMiD, and Anti-CD38 Antibody

What this Trial Is About

Researchers are evaluating the effectiveness of JNJ-79635322 in adults with Relapsed or Refractory Multiple Myeloma RRMM, a type of cancer affecting plasma cells. This study focuses on participants who have already undergone at least three previous treatments, including specific therapies such as proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies. The study is conducted in a Phase 2, open-label format to assess how well this treatment works in this patient group. Participants will receive JNJ-79635322 through injections under the skin. The study involves a single group where all participants receive this investigational drug. The treatment period lasts up to two years and nine months, during which the medications effects and participants responses are closely monitored. Throughout the study, participants will undergo regular assessments to measure various outcomes, including overall response rate, survival times, symptom changes, and quality of life using specialized questionnaires. Researchers will also monitor safety by tracking adverse events and checking for antibodies against the drug. The total participation duration may last up to nearly three years, allowing comprehensive evaluation of both effectiveness and safety over time.

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma